NImmune Biopharma Presented New Data at ACG 2026 Supporting the Efficacy and Safety of Innovative LANCL2 Medicines Targeting a Novel Mechanism in Hard — to — Treat IBD
For best results when printing this announcement, please click on link below: NImmune Biopharma Presented New Data at ACG 2026 Supporting the Efficacy and Safety of Innovative LANCL2 Medicines Targeting a Novel Mechanism in Hard-to-Treat IBD New clinical data show omilancor reduced a molecular signature associated with